Figure 6

Dogs treated with topical netarsudil BID for 8 months demonstrated variable disease progression. (A) Left eye of a 11-year-old neutered male Boston terrier diagnosed with PCED that received topical netarsudil for 8 months. The corneal edema was stable during the study (A1, A2) and the ECD increased from 944 ± 443 cells/mm² (A3) to 1978 ± 123 cells/mm² (A4). Corneal thickness remained stable (A5—575 μm, A6—624 μm). (B) Right eye of a 9.5-year-old neutered male boxer diagnosed with PCED that received topical netarsudil for 8 months. The area of the cornea affected by edema was stable during the study with 12.3% of the cornea affected by edema at baseline (B1) and 7% after 8 months of treatment (B2), as well as ECD (356 ± 107 cells/mm² at baseline, B3, and 389 ± 212 cells/mm² after 8 months, B4) and CCT (695 μm at baseline, B5, and 662 μm after 8 months, B6). (C) Left eye of a 11-year-old spayed female Chihuahua mix diagnosed with PCED that received topical netarsudil for 8 months. While the area of the cornea affected by edema remained stable during the study (34.8% at baseline, C1, and 41.3% after 8 months, C2), there was a decrease in ECD from 856 ± 175 cells/mm² (C3) to 478 ± 32 cells/mm² (C4). Central corneal thickness increased from 790 μm (C5) to 1171 μm (C6). Bar on IVCM images = 100 μm. Bar on FD-OCT images = 250 μm.